Last reviewed · How we verify

Spevigo — Competitive Intelligence Brief

Spevigo (SPESOLIMAB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-36 Receptor Antagonist [EPC]. Area: Immunology.

marketed Interleukin-36 Receptor Antagonist [EPC] Interleukin-1 receptor-like 2 Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Spevigo (SPESOLIMAB) — Boehringer Ingelheim Pharmaceuticals Inc. Spevigo works by blocking the interleukin-36 receptor, which plays a key role in the development of psoriasis symptoms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Spevigo TARGET SPESOLIMAB Boehringer Ingelheim Pharmaceuticals Inc marketed Interleukin-36 Receptor Antagonist [EPC] Interleukin-1 receptor-like 2 2022-01-01
SPEVIGO SPESOLIMAB-SBZO BOEHRINGER INGELHEIM PHARMACEUTICALS INC marketed Interleukin-36 Receptor Antagonist [EPC] Interleukin-1 receptor-like 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-36 Receptor Antagonist [EPC] class)

  1. BOEHRINGER INGELHEIM PHARMACEUTICALS INC · 1 drug in this class
  2. Boehringer Ingelheim Pharmaceuticals Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Spevigo — Competitive Intelligence Brief. https://druglandscape.com/ci/spesolimab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: